Printer Friendly

SMITHKLINE BEECHAM AND YALE UNIVERSITY ANNOUNCE AGREEMENT ON LYME DISEASE VACCINE

 SMITHKLINE BEECHAM AND YALE UNIVERSITY
 ANNOUNCE AGREEMENT ON LYME DISEASE VACCINE
 PHILADELPHIA, July 22 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) and Yale University today announced an agreement on the development of a vaccine against Lyme disease.
 Under the agreement, SmithKline Beecham has acquired a worldwide exclusive license to Yale patents relating to Lyme disease. The agreement provides for the use by SmithKline Beecham of technology and antigenic material developed by Yale, which will allow the development of a vaccine that covers the various antigenic types of the bacteria involved in the pathogenesis of Lyme disease and further enhances the current Lyme disease vaccine development programs at SmithKline Beecham. SmithKline Beecham will pay license fees to Yale as well as a royalty once the vaccine is marketed.
 Yale Research Dates to 1975
 Since 1975, Yale medical faculty physicians and scientists have conducted significant research on Lyme disease. They have also provided considerable patient care. The Yale work being licensed derives from research performed by an interdisciplinary team including Stephen W. Barthold, D.V.M., Ph.D., Professor of Comparative Medicine; Erol Fikrig, M.D., a postdoctoral fellow in immunobiology and infectious diseases; Richard A. Flavell, Ph.D., professor and chairman of immunobiology at Yale and a Howard Hughes Medical Institute investigator; and Fred S. Kantor, M.D., the Paul B. Beeson Professor of Medicine.
 During the last four years, the interdisciplinary team has made several important advancements, including producing a genetically engineered vaccine that successfully protects laboratory mice against experimentally induced Lyme disease.
 Barthold and his colleagues were the first to develop a laboratory model for Lyme arthritis using rats and mice; this model enables scientists to look inside to try to find ways of minimizing the disease in man and animals.
 Lyme disease is named for the Connecticut town where Yale rheumatologists, Dr. Stephen E. Malawista, professor of medicine, and Dr. Allen C. Steere, now at Tufts University, identified the first cluster of patients in 1975. The disease is usually caused when the bite of a tiny deer tick transmits a spiral-shaped bacterium, or spirochete, called Borrelia burgdorferi. Left untreated, it can cause debilitating arthritic symptoms, heart problems, skin lesions and neurological disorders.
 Agreement Enhances SmithKline Beecham's Vaccine Strategy
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines, and clinical laboratory testing services. The company's flagship vaccine is Engerix-B, the world's leading genetically engineered vaccine against hepatitis B infection. SB Biologicals, the company's human vaccine unit headquartered in Belgium, is the world's largest supplier of polio vaccine, and introduced Havrix , the world's first hepatitis A vaccine, in Europe in early 1992.
 Currently under development are broad spectrum pediatric vaccines. New candidate vaccines against herpes, malaria and influenza are in clinical trials; the vaccine against Lyme disease is at the preclinical state; and clinical trials are expected to start in 1993.
 "This agreement is a significant additional step in our strategy of leadership in the vaccines market in the U.S. and worldwide," said Jan Leschly, chairman, Pharmaceuticals, SmithKline Beecham. "The growing emphasis on preventive medicine, for both health and economic reasons, is giving vaccines an increasingly important role in health care."
 /delval/
 -0- 7/22/92
 /CONTACT: Sharyn Arnold of SmithKline Beecham, 215-751-7074, or Helaine Patterson of Yale University School of Medicine, 203-785-5824/
 (SBH) CO: SmithKline Beecham; Yale University School of Medicine ST: Pennsylvania; Connecticut IN: MTC SU: JVN


CC -- PH012 -- 1711 07/22/92 09:08 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 22, 1992
Words:578
Previous Article:HBO & COMPANY POSTS POSITIVE EARNINGS FOR FOURTH CONSECUTIVE QUARTER
Next Article:FIRST COMMUNITY BANCORP TO JOIN BANC ONE
Topics:


Related Articles
SMITHKLINE BEECHAM BIOLOGICALS RECEIVES FDA LICENSE TO MARKET HAVRIX, THE WORLD'S FIRST HEPATITIS A VACCINE
SMITHKLINE BEECHAM CITES RIBI IMMUNOCHEM'S MPL FOR SIGNIFICANT IMPROVEMENT OVER TRADITIONAL ADJUVANTS IN A HERPES VACCINE
RIBI COMPLETES ADJUVANT LICENSE AGREEMENT FOR NEW SMITHKLINE BEECHAM PHARMA ALLERGY VACCINES IN DEVELOPMENT
Ribi, SmithKline Beecham Expand Use of Ribi Adjuvants to New SB Vaccines in Development
U.S. Food And Drug Administration Licenses INFANRIX(TM) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed)
Genelabs Receives Additional $1 Million Payment From SmithKline Beecham For Expanded Rights to Hepatitis E Virus Vaccine.
SmithKline Beecham Announces Laboratory Services Agreement With Aetna U.S. Healthcare.
SmithKline Beecham and SkyePharma Sign Agreement to Develop Once-Daily Requip.
Coley Pharmaceutical Group and SmithKline Beecham Sign Collaboration.
MedImmune Grants SmithKline Beecham an Exclusive Worldwide License to Streptococcus Pneumoniae Vaccine Technology.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters